ERBB2 and breast carcinoma: The Oncotype DX Breast Recurrence Score® test is a validated clinical tool that predicts benefit of adjuvant chemotherapy in patients with ER+, HER2-negative, node-negative [21–25], and node-positive [24, 26] early breast cancer who receive five years of hormonal therapy.